List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials 22
Clinical Trials by Phase in E7 Countries 24
Clinical Trials in E7 Countries by Trial Status 25
Clinical Trials by Phase 26
In Progress Trials by Phase 28
Clinical Trials by Trial Status 29
Clinical Trials by End Point Status 31
Subjects Recruited Over a Period of Time 32
Clinical Trials by Sponsor Type 33
Prominent Sponsors 34
Top Companies Participating in Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials 36
Prominent Drugs 38
Latest Clinical Trials News on Crohn's Disease (Regional Enteritis) 39
Nov 22, 2019: Abivax to expand Phase IIb ulcerative colitis trial to France 39
Nov 06, 2019: Protagonist Therapeutics announces first patient dosed in a phase 2 study of oral IL-23 receptor antagonist PTG-200 (JNJ-67864238) in the treatment of Crohn's Disease 39
Oct 28, 2019: Formycon announces start of phase I clinical trial with Ustekinumab Biosimilar candidate FYB202 39
Oct 28, 2019: RedHill Biopharma to Present New Phase 3 Data on RHB-104 at the American College of Gastroenterology 2019 Annual Meeting 40
Oct 23, 2019: Provention Bio reports mixed results from Crohn's disease study 40
Oct 21, 2019: Retrospective real-world comparative analysis highlights safety of vedolizumab and Anti-TNFa therapies in biologic-naïve patients with Ulcerative Colitis or Crohn's Disease 40
Oct 21, 2019: Biogen and Samsung Bioepis to present data for Adalimumab biosimilar at United European Gastroenterology Week 41
Oct 17, 2019: NeuClone announces first human dose of Stelara (Ustekinumab) Biosimilar candidate in phase I clinical trial 42
Oct 11, 2019: RedHill Biopharma announces full results from positive MAP US phase 3 study and supportive top-line results from MAP US2 open-label extension study with RHB-104 in Crohn's Disease 42
Sep 27, 2019: Takeda reports further results from VARSITY ulcerative colitis study 43
Clinical Trial Profile Snapshots 44
Appendix 938
Abbreviations 938
Definitions 938
Research Methodology 939
Secondary Research 939
About GlobalData 940
Contact Us 940
Source 941

List of Tables
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Region, 2019* 8
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 10
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, North America, Top Countries, 2019* 14
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019* 15
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 16
Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, G7 Countries (%), 2019* 18
Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 21
Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, E7 Countries (%), 2019* 23
Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24
Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 26
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Phase, 2019* 27
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 28
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 30
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 31
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 32
Crohn's Disease (Regional Enteritis) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 33
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 35
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 37
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 38

List of Figures
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019* 15
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 16
Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, G7 Countries (%), 2019* 17
Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20
Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, E7 Countries (%), 2019* 22
Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24
Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Phase (%), 2019* 26
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 28
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 29
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 31
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 32
Crohn's Disease (Regional Enteritis) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 33
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 34
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 36
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 38
GlobalData Methodology 900

Companies Mentioned
- Takeda Pharmaceutical Co Ltd
- AbbVie Inc
- Johnson & Johnson
- UCB SA
- Pfizer Inc
- Bristol-Myers Squibb Co
- Merck & Co Inc
- Abbott Laboratories
- C. H. Boehringer Sohn AG & Co KG
- IQVIA Holdings Inc